In 2023, Kindbody was valued at $1.8B and promised to remake fertility care. This month, it lost its CEO, sold its Midwest clinics, and put every remaining clinic up for sale. The company plans to operate as strictly a FBM moving forward.

The news has led to questions from providers and patients, including mid-cycle patients who are uncertain of where their care now stands.

We tracked how the organization moved from rapidly expanding to selling all its clinics in our new white paper.

What’s inside:

- A timeline of Kindbody’s troubles, from its 2022 acquisitions to this week’s clinic sales

- How the valuation fell by two-thirds, and what that signaled

- Eight warning signs to watch for in fertility care

- Four steps clinics can take now to protect revenue, reputation and patients